Forte Biosciences (FBRX)
(Delayed Data from NSDQ)
$0.58 USD
-0.01 (-1.77%)
Updated Jun 7, 2024 03:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FBRX 0.58 -0.01(-1.77%)
Will FBRX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for FBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FBRX
What Makes Forte Biosciences (FBRX) a New Buy Stock
FBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for FBRX
Forte Biosciences initiated with bullish view at Brookline, here's why
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Edgewise Therapeutics (EWTX) and Forte Biosciences (FBRX)
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
FBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024